Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 27
Filter
Add more filters










Publication year range
1.
Eur J Intern Med ; 18(5): 423-9, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17693232

ABSTRACT

BACKGROUND: Subclinical hyperthyroidism (SH) is defined by suppressed TSH and normal levels of thyroid hormones. Endogenous subclinical hyperthyroidism (ESH) is probably less common than exogenous SH. Adverse effects of SH due to exogenous administration of thyroxine have been well studied, while the impact of ESH on the cardiovascular system and metabolic parameters remains controversial. METHODS: In a cross-sectional study, we examined patients with endogenous clinical hyperthyroidism (ECH; n=20), ESH (TSH<0.1 muU/mL, n=25), and mild ESH (TSH=0.1-0.3 muU/mL, n=32), as well as healthy controls (n=50). Biochemical and metabolic parameters influenced by thyroid hormones were assessed and cardiac parameters were studied using echocardiography and 24-hour ECG-blood pressure monitoring. RESULTS: Biochemical and metabolic parameters did not differ significantly between ESH and healthy subjects. The ECH group had significantly higher sex hormone-binding globulin, osteocalcin, and carboxy-terminal telopeptide levels than healthy subjects. No significant differences were noted in echocardiographic parameters between ESH patients and healthy subjects. The ECH group had a significantly higher heart rate, cardiac output, and cardiac index than the control group, as well as end-diastolic and end-systolic diameters of the left ventricle, and end-diastolic and end-systolic volumes of the left ventricle. The 24-hour ECG-blood pressure monitoring parameters did not differ significantly either between SH and healthy subjects while, in the ECH group, mean heart rate, maximum heart rate, and mean tachycardia episodes were significantly increased. CONCLUSION: Only subjects with ECH showed differences in metabolic and cardiac parameters from controls, while no significant effects were noted in the endogenous subclinical forms.

2.
Acta Neurol Scand ; 106(1): 58-61, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12067331

ABSTRACT

Neurofibromas are a hallmark of neurofibromatosis type 1 (NF1). They are usually benign and rarely present in the thyroid gland region. There is a suspected association between NF1 and intramedullary thyroid carcinoma and there is a well-known association between NF1 and pheochromocytoma. Here, we present a 55-year-old man with typical symptoms of NF1, whose course was complicated by a neurofibroma of the thyroid gland. His clinical spectrum of symptoms included bilateral cataract established before the age of 35 years, quadriparesis and an intrathoracic mass. The patient died because of abdominal carcinomatosis of unknown origin. The rarity of thyroid gland neurofibroma is discussed here, emphasizing the importance of early detection of these and other NF1 complications, also including the risk of malignant transformation with lethal outcome.


Subject(s)
Abdominal Neoplasms/complications , Carcinoma/complications , Neurofibroma/diagnosis , Neurofibromatosis 1/complications , Thoracic Neoplasms/complications , Thyroid Neoplasms/diagnosis , Biopsy , Cataract/complications , Fatal Outcome , Humans , Magnetic Resonance Imaging , Male , Medical Illustration , Middle Aged , Neurofibroma/complications , Neurofibromatosis 1/diagnosis , Thoracic Neoplasms/diagnosis , Thyroid Neoplasms/complications , Tomography, X-Ray Computed
3.
Thyroid ; 10(6): 493-7, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10907993

ABSTRACT

OBJECTIVE: Previous studies, mostly performed in iodine-deficient areas, have suggested that the administration of iodine to patients with endemic goiter may be associated with the development of thyroid autoantibodies (ThAbs); however, this has not been a consistent finding. In this study, we evaluated the effect of iodine on thyroid function and on the development of indices of autoimmunity (ThAbs and lymphocytic infiltration) in an iodine replete area. METHODS: Iodized oil (1 mL) was administered intramuscularly to 40 euthyroid patients with nontoxic goiter, adequate iodine intake, and absent or normal levels of ThAbs. Blood and urinary samples were taken at time 0, 3, 6, and 12 months after iodine administration. Thyroid volume was evaluated and fine-needle aspiration (FNA) was performed at 0, 6, and 12 months. RESULTS: Seven patients developed abnormal levels of ThAbs at some time between 3 and 12 months after iodine administration (p = 0.017). Mean anti-thyroglobulin (Tg) antibody levels increased at 6 months without reaching abnormal levels, but did not reach statistical significance (p = 0.062). Lymphocytic infiltration was detected in FNA smears in 10 cases before and in 27 cases after treatment (p = 0.0003). Triiodothyronine (T3) decreased at 12 months of follow-up, while thyroxine (T4) and thyrotropin (TSH) levels did not change significantly. A decrease in the mean levels of thyroglobulin as well as a small reduction in goiter size was observed at 6 and 12 months. CONCLUSION: The administration of iodized oil to patients with small nontoxic goiter in an iodine-replete area was accompanied by the development of abnormal levels of ThAbs in some cases and by an increase in thyroid lymphocytic infiltration.


Subject(s)
Goiter/drug therapy , Iodine/therapeutic use , Thyroiditis, Autoimmune/drug therapy , Adult , Autoantibodies/analysis , Female , Goiter/diagnostic imaging , Goiter/pathology , Humans , Immunoradiometric Assay , Lymphocytes/drug effects , Male , Middle Aged , Organ Size/drug effects , Thyroid Hormones/blood , Thyroiditis, Autoimmune/diagnostic imaging , Thyroiditis, Autoimmune/pathology , Ultrasonography
4.
Thyroid ; 9(10): 973-7, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10560950

ABSTRACT

A coexistence of mitral valve prolapse (MVP) with autoimmune thyroid disease (AITD) has been described, but there are not sufficient data to explain this association. The aim of the present study was to investigate the prevalence of MVP in patients with AITD and to evaluate whether any correlation between MVP and certain immunological parameters exists. M-mode, two-dimensional Doppler echocardiography was performed in 29 patients with Graves' disease (GD), 35 with Hashimoto's thyroiditis (HT), 20 with nonautoimmune goiter, and 30 normal controls. Serum samples were examined for antinuclear antibodies (ANA), antibodies against extractable nuclear antigen (ENA), antiphospholipid antibodies (aCL), rheumatoid factor (RF), thyroid autoantibodies (TAAb), immunoglobulins and C3, C4. Eight of 29 GD patients and 8 of 35 HT patients had MVP, while none of the control group and 2 of 20 of the simple goiter group had MVP (p < 0.05). ANA were detected at low titers in 5 of 8 in MVP(+) GD versus 3 of 21 in MVP(-) GD (p < 0.05). In the HT group the MVP(+) patients had a significantly higher incidence of ANA and ENA, 5 of 8 and 2 of 8 versus 5 of 27 and 0 of 27 of MVP(-) patients, respectively, p < 0.05. A statistically significant higher incidence of aCL was found in HT MVP(+) patients. (3/8) versus HT MVP(-) 1/27, p < 0.05. RF levels (immunoglobulin A [IgA]) were significantly higher in MVP(+) patients. The association of MVP with nonorgan-specific autoantibodies indicates that MVP may also be an autoimmune disease. It is possible that patients with AITD who also have MVP may be at an increased risk to develop systemic autoimmunity.


Subject(s)
Autoimmune Diseases/complications , Mitral Valve Prolapse/etiology , Thyroid Diseases/complications , Adult , Antibodies, Antinuclear/blood , Antibodies, Antiphospholipid/blood , Antigens, Nuclear , Autoantibodies/blood , Autoimmune Diseases/immunology , Echocardiography, Doppler , Female , Goiter/complications , Graves Disease/complications , Graves Disease/immunology , Humans , Male , Middle Aged , Mitral Valve Prolapse/diagnostic imaging , Nuclear Proteins/immunology , Rheumatoid Factor/blood , Thyroid Diseases/immunology , Thyroid Gland/immunology , Thyroiditis, Autoimmune/complications , Thyroiditis, Autoimmune/immunology
5.
Eur J Endocrinol ; 140(6): 505-11, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10366406

ABSTRACT

Endemic non-toxic goiter (NTG) in Greece has been attributed primarily to iodine deficiency. Thirty years ago about 60% of the prepubertal boys and girls examined in endemic goiter regions presented with NTG and among them thyroid autoimmunity was rarely detected. Although iodine supplementation has corrected this deficiency during the past 30 years, new cases of NTG still appear. To evaluate the prevalence and type of NTG and the effect of iodine supplementation on them in Greece at present, we performed two cross-sectional clinical studies and a retrospective pathology one: (i) thyroid gland volume and urinary iodine excretion (UIE) were assessed in a representative sample of 1213 schoolchildren from previously endemic and non-endemic regions; (ii) serum thyroxine, tri-iodothyronine, TSH, thyroid autoantibodies (AAB) (anti-thyroid peroxidase and anti-thyroglobulin antibodies) and UIE (in 60 patients) were measured in 300 consecutive patients with NTG from Athens and Heraklion; and (iii) we compared the prevalence of autoimmunity among fine needle aspiration smears of benign thyroid pathologies performed by the same pathologist between 1985 and 1986 (975 cases) and between 1994 and 1995 (2702 cases). We found that 12. 5% of the schoolchildren examined in regions with a previous history of endemic goiter had NTG, whereas this percentage was only 1.7% in areas without such a history. In Athens (61.6%) and Heraklion (58. 5%) a substantial number of NTG patients were AAB positive and biochemically hypothyroid. UIE in Athens did not differ between patients with autoimmune goiter (ATG) and simple goiter. The prevalence of autoimmune stigmata in pathology smears has increased from 5.94% (years 1985-1986) to 13.91% (years 1994-1995) (P<0.05). We conclude that: (i) the persistence of endemic goiter in regional foci despite iodine deficiency correction suggests a possible role for a naturally occurring goitrogen; (ii) ATG is the predominant form of NTG in Greece nowadays; and (iii) the five-fold decrease in the prevalence of NTG during the past 30 years followed by the increase of ATG may support the relative character of the latter.


Subject(s)
Thyroiditis, Autoimmune/epidemiology , Autoantibodies/analysis , Biopsy, Needle , Child , Goiter, Endemic/epidemiology , Goiter, Endemic/pathology , Greece/epidemiology , Humans , Iodine/deficiency , Iodine/therapeutic use , Iodine/urine , Prevalence , Retrospective Studies , Thyroid Gland/immunology , Thyroid Gland/pathology , Thyroiditis, Autoimmune/pathology
6.
Eur J Endocrinol ; 138(2): 141-5, 1998 Feb.
Article in English | MEDLINE | ID: mdl-9506856

ABSTRACT

OBJECTIVE: The association between established hypothyroidism and high cholesterol levels is well known. The aim of the present study was to investigate the effect of thyroxine (T4) administration on cholesterol levels in hypercholesterolemic subjects with TSH levels within the normal range ('high-normal' TSH compared with 'low-normal' TSH). DESIGN AND METHODS: We determined TSH levels in 110 consecutive patients referred for hypercholesterolemia (serum cholesterol >7.5 mmol/l). Those with 'high-normal' TSH (2.0-4.0 microU/ml) as well as those with 'low-normal' TSH (0.40-1.99 microU/ml) were randomly assigned to receive either 25 or 50 microg T4 daily for two months. Thus, groups A and B (low-normal TSH) received 25 and 50 microg T4 respectively and groups C and D (high-normal TSH) received 25 and 50 microg T4 respectively. Serum T4, tri-iodothyronine (T3), TSH, free thyroxine index, resin T3 uptake and thyroid autoantibodies (ThAab) as well as total cholesterol, high and low density lipoprotein cholesterol (HDL, LDL), and triglycerides were determined before and at the end of the two-month treatment period. RESULTS: TSH levels were reduced in all groups. The most striking effect was observed in group D (TSH levels before: 2.77+/-0.55, after: 1.41+/-0.85 microU/ml, P < 0.01). Subjects in groups C and D had a higher probability of having positive ThAabs. A significant reduction in total cholesterol (P < 0.01) and LDL (P < 0.01) was observed after treatment only in group D. In those subjects in group D who were ThAab negative, there was no significant effect of thyroxine on cholesterol levels. CONCLUSIONS: Subjects with high-normal TSH levels combined with ThAabs may, in fact, have subclinical hypothyroidism presenting with elevated cholesterol levels. It is possible that these patients might benefit from thyroxine administration.


Subject(s)
Cholesterol/blood , Hypothyroidism/blood , Thyrotropin/blood , Adult , Aged , Autoantibodies/analysis , Female , Humans , Iodide Peroxidase/immunology , Lipoproteins/blood , Male , Middle Aged , Thyroglobulin/immunology , Thyroxine/therapeutic use , Triglycerides/blood
7.
Thyroid ; 7(3): 411-4, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9226212

ABSTRACT

Patients with hypothyroidism are considered to have an increased risk of developing atherosclerosis; because endothelial dysfunction is an early sign of atherosclerosis, we investigated whether endothelial dysfunction is present in patients with hypothyroidism. Thirty-five subjects with various TSH levels were investigated by high-resolution ultrasound imaging of the brachial artery to assess endothelial and smooth muscle responses. Flow-mediated, endothelium-dependent vasodilatation was significantly higher in subjects with TSH 0.4-2 microIU/mL (11.8 +/- 2.7%), compared with subjects with TSH 2.01-4 microIU/mL (6.8 +/- 2.9%), 4.01-10 microIU/mL (5.2 +/- 6.3%) and >10 microIU/mL (4.0 +/- 4.4%); TSH levels correlated inversely to endothelium-dependent dilatation. Thus, flow-mediated vasodilatation, a marker of endothelial function, is impaired not only in patients with mild hypothyroidism but also in subjects with "high-normal" serum TSH levels (ie, 2.01-4.0 microIU/mL) that may be characterized as possibly abnormal.


Subject(s)
Endothelium, Vascular/physiology , Hypothyroidism/physiopathology , Thyrotropin/blood , Vasodilation/physiology , Adult , Brachial Artery/diagnostic imaging , Brachial Artery/physiopathology , Female , Humans , Hypothyroidism/blood , Hypothyroidism/diagnostic imaging , Male , Regression Analysis , Thyroxine/blood , Triiodothyronine/blood , Ultrasonography
8.
Thyroidology ; 5(1): 1-7, 1993 Apr.
Article in English | MEDLINE | ID: mdl-7508737

ABSTRACT

Thirty four sera from: 12 patients with Systemic Lupus Erythematosus (SLE), 9 with Subacute Cutaneous Lupus Erythematosus (SCLE) and 13 with Discoid Lupus Erythematosus (DLE) (disseminatus 3, localised 10) were tested for the presence of: (a) anti-thyroglobulin and anti-microsomal autoantibodies (b) anti-Sm/RNP, anti-doublestranded. DNA (anti-ds. DNA), anti-single-Stranded. DNA (anti-ss. DNA), anti-cardiolipin (anti-Cl), anti-SSA, anti-SSB, Antinuclear Antibodies (ANA). T3, T4, TSH levels were also determined. Five patients with SLE (41.6%), 4 with SCLE (44.4%), and 2 with DLE (15.3%) had thyroid autoantibodies and only three of the 41 controls (7.3%). Five patients (14.7%), especially from SLE and SCLE groups, had biochemical hypothyroidism whereas only one had hyperthyroidism. Statistical evaluation for the possible coexistence of thyroid autoantibodies with a panel of lupus characteristic autoantibodies, revealed highly significant correlations with anti-Sm/RNP, IgG (p = 0.003) and anti-ds. DNA, IgM (p = 0.012). It may be concluded, that not only SLE but also SCLE predisposes to autoimmune thyroid disease and the prevalence of the latter is related to a great extent to the subset of the LE spectrum. From these results and from the inhibition experiments, it seems that some of the specific mono- or polyclonal autoantibodies may be multiple organ reactive.


Subject(s)
Autoantibodies/blood , Lupus Erythematosus, Cutaneous/immunology , Lupus Erythematosus, Discoid/immunology , Lupus Erythematosus, Systemic/immunology , Ribonucleoproteins, Small Nuclear , Thyroid Gland/immunology , Thyroid Gland/physiopathology , Adult , Antibodies, Antinuclear/blood , Autoantigens/immunology , Female , Humans , Immunoglobulin M/blood , Lupus Erythematosus, Cutaneous/physiopathology , Lupus Erythematosus, Discoid/physiopathology , Lupus Erythematosus, Systemic/physiopathology , Male , snRNP Core Proteins
9.
Clin Endocrinol (Oxf) ; 36(6): 573-8, 1992 Jun.
Article in English | MEDLINE | ID: mdl-1424182

ABSTRACT

OBJECTIVE: To clarify the duration and the extent of the antithyroid effect of iodides in hyperthyroidism, and to investigate whether iodides have an additional peripheral effect on the metabolism of thyroid hormones, as has been reported for some organic iodine compounds. DESIGN: The effect on the peripheral thyroid hormone levels of 150 mg of potassium iodide daily (equivalent to 114 mg of iodide) for 3-7 weeks was compared in 21 hyperthyroid patients and 12 healthy controls. A possible effect of iodide on the peripheral metabolism of thyroid hormones was investigated by assessing the serum levels of thyroid hormone in 12 hypothyroid patients on thyroxine replacement for 2 weeks. PATIENTS: There were 21 thyrotoxic patients, 12 healthy hospital controls, and 12 patients with complete or near-complete hypothyroidism, on thyroxine replacement. MEASUREMENTS: The following were measured before and at weekly intervals after iodide administration: (1) pulse rate, (2) serum T4, (3) serum T3, (4) serum TSH, (5) serum thyroxine-binding capacity (TBC), (6) serum rT3, (7) serum thyroxine-binding globulin (TBG), (8) the free-T4 Index, calculated as T4/TBC. RESULTS: In the hyperthyroid patients serum T4, T3 and rT3 decreased, whereas serum thyroxine-binding globulin and thyroxine binding capacity increased. Serum T3, however, did not become completely normal in all cases. After 21 days, serum T4 and T3 started increasing again in some cases, but other patients remained euthyroid even after 6 weeks. In the normal controls there was a small but significant and consistent decrease in serum T4, T3 and rT3 and an increase in serum TSH. Finally, in the T4-treated hypothyroid patients there was no consistent change, except for an increase of serum T4 at 1 and 14 days and a decrease of serum TSH the first day. CONCLUSION: Iodides in hyperthyroidism have a variable and unpredictable intensity and duration of antithyroid effect. Their antithyroid effect is smaller in normal controls. They have no important effect on the peripheral metabolism of thyroid hormones.


Subject(s)
Hyperthyroidism/blood , Hypothyroidism/blood , Potassium Iodide/pharmacology , Thyroid Gland/drug effects , Thyroid Hormones/blood , Thyroxine/therapeutic use , Adult , Aged , Female , Humans , Hypothyroidism/drug therapy , Male , Middle Aged , Thyrotropin/blood , Thyroxine/blood , Triiodothyronine/blood , Triiodothyronine, Reverse/blood
10.
J Endocrinol Invest ; 14(9): 743-6, 1991 Oct.
Article in English | MEDLINE | ID: mdl-1761809

ABSTRACT

Serum thyroid hormones and antithyroid autoantibodies (AAB) were assayed in 87 randomly selected hypercholesterolemic persons compared to 80 controls with normal serum total cholesterol (TC). Of the 87 hypercholesterolemic persons 22 (25%) had positive AAB compared to 5 (6%) controls. Furthermore, 8 of the hypercholesterolemic patients had a serum TSH level above 5 mU/l, i.e. the had subclinical hypothyroidism, not diagnosed before, whereas thyroid function was normal in all normocholesterolemic persons. The new and unexpected finding was that the hypercholesterolemic persons had on average a significantly higher serum TSH than the controls, and this was true even when persons with positive AAB were excluded. There was a significant correlation between TC and serum TSH. It is concluded that hypothyroidism may not be an all-or-none phenomenon, and that many hypercholesterolemic persons with thyroid tests within the conventional normal range may have a slight impairment of their thyroid function.


Subject(s)
Hypercholesterolemia/blood , Hypothyroidism/complications , Thyrotropin/blood , Female , Humans , Hypercholesterolemia/complications , Male , Thyroxine/blood , Triiodothyronine/blood
11.
Exp Clin Endocrinol ; 97(2-3): 308-11, 1991 May.
Article in English | MEDLINE | ID: mdl-1915648

ABSTRACT

Potassium iodide was given to 17 cases of Basedow's disease in comparison to 12 normal controls for 5 weeks. In the thyrotoxic patients, the maximum decrease in serum T3 and T4 levels was observed 2 and 3 weeks, respectively, but in some cases remained normal even at 5 weeks. The euthyroid persons showed a small decrease in T4 and T3 and an increase in serum TSH.


Subject(s)
Graves Disease/drug therapy , Potassium Iodide/therapeutic use , Adult , Female , Humans , Hyperthyroidism/drug therapy , Male , Thyrotropin/blood , Thyroxine/blood , Triiodothyronine/blood
12.
Thyroidology ; 2(2): 81-8, 1990 Aug.
Article in English | MEDLINE | ID: mdl-1724914

ABSTRACT

We treated 204 patients with endemic nontoxic goiter with T4, T3 and KI, singly or in combination. Definitely nodular goiters were excluded, since the possibility of autonomy would be increased. Goiter size was evaluated before and 6 months after treatment clinically in a blind way, i.e. the observer (always the same) did not know either the pretreatment goiter size or the treatment the patient had received. At the same time various laboratory parameters were recorded. All the active treatments (but not placebo) resulted in a highly significant decrease in the gland size. The effectiveness decreased in the following order: 1) T3 50 micrograms/d (most effective), 2) (T4 50 micrograms/d + T3 12.5 micrograms) x 2, 3) T4 150 micrograms + iodide 150 micrograms/d, 4) T4 75 micrograms + T3 18.75 micrograms/d, 5) T4 200 micrograms/d, 6) T3 37.5 micrograms/d, 7) Iodide 300 micrograms/d, 8) T4 150 micrograms/d, 9) Iodide 150 micrograms/d (least effective) and 10) Placebo (not effective). The results show that T4 200 micrograms and T3 50 micrograms are roughly equipotent, and slightly more effective than 300 micrograms of Iodide. Taking into consideration the side effects (increase in pulse rate, shortening of the Achilles tendon reflex) did not change the order of effectiveness in an important way. The clinical outcome correlated in general with the suppression of the 131I uptake (r = 0.220, p = 0.03) and the TRH test (r = 0.248, p = 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Goiter, Endemic/drug therapy , Potassium Iodide/therapeutic use , Thyroxine/therapeutic use , Triiodothyronine/therapeutic use , Autoantibodies/drug effects , Creatinine/urine , Drug Combinations , Goiter, Endemic/immunology , Humans , Iodine Radioisotopes , Microsomes/immunology , Potassium Iodide/adverse effects , Potassium Iodide/pharmacology , Pulse/drug effects , Random Allocation , Thyroglobulin/immunology , Thyroid Gland/drug effects , Thyrotropin/blood , Thyroxine/adverse effects , Thyroxine/pharmacology , Triiodothyronine/adverse effects , Triiodothyronine/pharmacology
13.
Endocrinol Exp ; 23(4): 269-78, 1989 Dec.
Article in English | MEDLINE | ID: mdl-2620658

ABSTRACT

This study examined whether or not the electrophysiological effect of amiodarone on the heart is mediated through its action on thyroxine metabolism. Serum thyroid hormones and ECG were evaluated before and serially during amiodarone (15 subjects) and benziodarone (15 subjects) administration. Both amiodarone and benziodarone shifted the peripheral conversion of thyroxine (P less than 0.001 for amiodarone and P less than 0.001 for benziodarone) towards reverse triiodothyronine and away from triiodothyronine, whilst TSH levels initially fell and then rose with both drugs. After amiodarone the heart rate decreased (P less than 0.025), whilst the PR (P less than 0.005) and the QT interval (P less than 0.005) corrected for the heart rate increased. By contrast with benziodarone only the PR interval decreased (P less than 0.05). Since both drugs had roughly similar effects on thyroid hormone metabolism but different ones on the ECG, our results provide indirect evidence against the hypothesis that the antiarrhythmic effects of amiodarone are mediated through a decrease in the serum T3 presented to the peripheral tissues.


Subject(s)
Amiodarone/pharmacology , Benzofurans/pharmacology , Electrocardiography/drug effects , Thyroxine/metabolism , Adolescent , Adult , Aged , Anti-Arrhythmia Agents/pharmacology , Female , Humans , Middle Aged , Thyrotropin/metabolism , Triiodothyronine
14.
Endocrinol Exp ; 22(3): 165-9, 1988 Sep.
Article in English | MEDLINE | ID: mdl-2851437

ABSTRACT

Hypocalcemia occurring a few days after total subtotal thyroidectomy has been attributed either to parathyroid insufficiency or to calcitonin release. To investigate this matter further, we measured serum calcium, phosphate, T3, T4, TSH, parathormone (PTH), calcitonin (CT) and cAMP, in 27 women aged 23 to 63 years, before and also 3 and 7 days after subtotal thyroidectomy for multinodular nontoxic goiter. Ca, T3 and T4 decreased, whereas TSH increased appropriately to the decrease in T4 and T3. There was no increase in PTH appropriate to the Ca decrease. In contrast, PTH, cAMP and CT showed statistically unsignificant tendency to decrease. It was concluded that hypocalcemia after thyroidectomy is not due to CT release, but rather to a relative PTH insufficiency.


Subject(s)
Parathyroid Glands/metabolism , Thyroid Gland/metabolism , Thyroidectomy , Adult , Calcitonin/blood , Calcium/blood , Cyclic AMP/blood , Female , Goiter/surgery , Humans , Middle Aged , Parathyroid Hormone/blood , Phosphates/blood , Thyrotropin/blood , Thyroxine/blood , Time Factors , Triiodothyronine/blood
15.
J Endocrinol Invest ; 11(6): 437-9, 1988 Jun.
Article in English | MEDLINE | ID: mdl-3209822

ABSTRACT

The urinary iodine excretion, expressed as the iodine/creatinine (I/Cr) ratio, was correlated with the serum T4 and TSH levels in persons with a relatively constant iodine intake for at least 6 months. It was found that the group with an I/Cr ratio of 151-200 micrograms/g had on average the lowest serum TSH and the highest serum T4 level. The differences in serum TSH from the other groups were statistically significant, whereas the differences in serum T4 were not. It is concluded that an I/Cr ratio of 151-200, corresponding to an iodine intake of about 200 micrograms/day, is associated with the lowest TSH stimulation of the thyroid gland in man and probably represents the optimal conditions for its function.


Subject(s)
Iodine/urine , Thyrotropin/blood , Thyroxine/blood , Adult , Female , Greece , Humans , Iodine/pharmacology , Male
16.
Chemioterapia ; 7(3): 195-7, 1988 Jun.
Article in English | MEDLINE | ID: mdl-3168076

ABSTRACT

Six female patients with medullary thyroid carcinoma were treated with doxorubicin (50 mg/m2) and cis-diammine dichloroplatinum (70 mg/m2) every three weeks. No patient responded to therapy as was suggested by serial serum calcitonin concentrations before and after treatment.


Subject(s)
Calcitonin/blood , Carcinoma/drug therapy , Thyroid Neoplasms/drug therapy , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols , Carcinoma/blood , Cisplatin/administration & dosage , Combined Modality Therapy , Doxorubicin/administration & dosage , Female , Humans , Middle Aged , Monitoring, Physiologic , Thyroid Neoplasms/blood , Thyroidectomy , Thyroxine/therapeutic use
17.
J Endocrinol Invest ; 9(4): 337-9, 1986 Aug.
Article in English | MEDLINE | ID: mdl-3491129

ABSTRACT

The effect of benziodarone on the levels of thyroid hormones in the serum has not attracted interest, in spite of the prolific literature on the related drug amiodarone. It is shown here that benziodarone administration has several effects, mainly similar to amiodarone, but some possibly opposite and inappropriate. Nine normal volunteers received benziodarone, 100 mg three times daily for 14 days. Before and 1, 3, 7 and 14 days after continuous administration the following estimates were obtained: serum T4, T3, rT3 and TSH, both basal (TSH0) and 30 min after iv administration of TRH (TSH30), the difference being calculated as delta TSH. Serum T4 remained relatively constant. Serum T3 decreased significantly from the 1st to the 14th day (eg. before 2.15 +/- 0.12 nmol/l, at 3 days 1.45 +/- 0.07). Serum rT3 increased significantly from the 1st to the 14th day (eg. before 0.71 +/- 0.16 nmol/l, at 7 days 2.61 +/- 0.19). Serum TSH0 and TSH30 decreased significantly on the 1st and 3rd day. Later they increased, and TSH0 at 14 days was significantly higher than the pre-treatment value. Our results suggest that benziodarone has an amiodarone-like action in diverting the peripheral metabolism of T4 towards rT3 rather than T3. However, the effects on the pituitary-thyroid axis are not similar to those previously reported by others and ourselves about amiodarone, and these merit further research.


Subject(s)
Benzofurans/pharmacology , Pituitary Gland/drug effects , Thyroid Gland/drug effects , Thyroid Hormones/blood , Adult , Female , Humans , Male , Middle Aged , Pituitary Gland/physiology , Thyroid Gland/physiology , Thyrotropin/blood , Thyroxine/blood , Triiodothyronine/blood , Triiodothyronine, Reverse/blood
18.
Endocrinol Exp ; 20(1): 57-65, 1986 Mar.
Article in English | MEDLINE | ID: mdl-3486112

ABSTRACT

108 patients with endemic nontoxic goitre have been treated in the field with thyroxine (T4), triiodothyronine (T3), and potassium iodide (KI), singly or in combination, or with placebo. After 6 months of continuous treatment, goitre size decreased significantly in the 7 actively treated groups, but not in the one treated with placebo. The combination of 150 micrograms T4 + 150 micrograms KI daily seemed the most effective treatment, both clinically and by its suppression of the 131I uptake and the TSH response to TRH, followed by 100 micrograms T4 + 25 micrograms T3 or 200 micrograms T4, but the difference from the other groups was not statistically significant. The increase in the pulse rate (PR) and the shortening of the photomotogram of the Achilles tendon reflex (PMG) were taken as indices of thyrotoxicity and side-effects of the treatment. There was no significant difference in the side-effects between any two of the active groups if effectiveness was also taken into account. The decrease in goitre size was not correlated to either the final serum T3 value achieved at the end of the treatment, or the thyroidal 131I uptake. There was, however, a weak but significant correlation between the decrease in goitre size and the TSH response to TRH. This casts some doubt to the concept that thyroid hormones decrease goitre size solely by suppressing the pituitary TSH release. Of the 30 patients treated with KI singly or in combination and studied in this respect, 8 developed autoantibodies against thyroglobulin and/or the thyroidal microsomal antigen compared to 1 of 22 not receiving KI (P = 0.08).(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Goiter, Endemic/drug therapy , Potassium Iodide/therapeutic use , Thyroxine/therapeutic use , Triiodothyronine/therapeutic use , Adolescent , Adult , Autoantibodies/analysis , Drug Therapy, Combination , Female , Goiter, Endemic/blood , Humans , Male , Middle Aged , Potassium Iodide/administration & dosage , Potassium Iodide/adverse effects , Thyroglobulin/immunology , Thyroid Gland/immunology , Thyroid Hormones/blood , Thyroxine/administration & dosage , Thyroxine/adverse effects , Triiodothyronine/administration & dosage , Triiodothyronine/adverse effects
20.
Endokrinologie ; 79(3): 349-54, 1982 Jul.
Article in English | MEDLINE | ID: mdl-7128549

ABSTRACT

In 534 unselected schoolchildren aged 6-14 yr from the greater Athens area the size of the thyroid gland was assessed by palpation, and information was obtained on sex, age, height, weight, skinfold thickness, socioeconomic class, eye colour and urinary iodine excretion. The results were analysed by discriminant analysis. Altogether 14% of these children had a thyroid enlargement (7% had a definite goitre and another 7% a smaller enlargement). The set of variables studied were significantly discriminatory (Wilk's lambda 0.926, p approximately equal to 0.004). Most of the discrimination was accounted for by height (positive association, b coefficient 0.0114, SE 0.0029, t = 3.95) and weight (negative association, b coefficient 0.0107, SE 0.0030, t = 3.61). No other parameter, including iodine excretion, showed a significant difference between goitrous and nongoitrous. It is concluded that the only genuine difference is that goitrous are heavier for a given height or shorter for a given weight, i.e. more obese. The reason for which obesity protects from sporadic nontoxic goitre is not entirely clear, but probably both nutritional and genetic factors are involved.


Subject(s)
Goiter/epidemiology , Thyroid Gland/pathology , Adolescent , Age Factors , Body Height , Body Weight , Child , Female , Greece , Humans , Male , Sex Factors , Skinfold Thickness , Socioeconomic Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...